Paper In Cancer Research Further Validates Ambit Biosciences Corporation’ KinomeScan Kinase Profiling Platform

Ambit Biosciences today announced the publication in the January 15, 2006 issue of the journal Cancer Research of a crystal structure that explains why the Aurora kinase inhibitor VX-680 is active against Gleevec(R) (imatinib)-resistant forms of the kinase BCR-ABL, including the T315I mutant variant. The T315I mutation is the most common drug-resistant mutation in chronic myelogenous leukemia (CML) and confers resistance not only to Gleevec, but to all second generation BCR-ABL inhibitors currently in clinical development. The interaction between VX-680 and BCR-ABL variants was initially identified using Ambit’s proprietary KinomeScan kinase profiling platform.

MORE ON THIS TOPIC